Arctic Bioscience – Exercise of right to convert debt and issuance of shares

Arctic Bioscience said an investor from the consortium behind a NOK 15 million convertible loan has exercised the right to convert NOK 270,365 of outstanding debt (including accrued interest) into equity at a conversion price of NOK 2.7896 per share; the board will issue the shares under authorization from the company’s May 26, 2025 general meeting, bringing shares outstanding to 26,956,257. The conversion is a small reduction of the company’s debt and a modest dilution relative to the total financing facility. Arctic Bioscience is a biotech developer of HRO350 for mild-to-moderate psoriasis and markets ROMEGA® nutraceutical products globally.

Analysis

Arctic Bioscience reported that an investor from the consortium behind a NOK 15.0 million convertible loan has converted NOK 270,365 of outstanding debt (including accrued interest) into equity at a conversion price of NOK 2.7896 per share; the Board will issue the shares under authorization granted by the company’s General Meeting on 26 May 2025, and shares outstanding will be 26,956,257 after the increase. The converted amount represents roughly 1.8% of the NOK 15.0 million facility and will add on the order of ~97 thousand new shares, implying a modest dilution of approximately 0.35–0.40% to the enlarged share base. The transaction reduces a small portion of the company’s debt and interest burden but does not meaningfully change the company’s capital structure or cash runway given the size of the remaining facility. Market signals attached to the release are neutral with a low estimated market impact (score ~0.08), suggesting the conversion is a routine financing mechanics event rather than a material operational development.

The conversion provides limited affirmative evidence of at least one investor’s willingness to hold equity rather than demand cash repayment, which could be interpreted as a minor confidence signal; however, it is insufficient to conclude a broader investor endorsement or to materially de-risk the company’s financing requirements. Core fundamental drivers remain product development and commercialization: HRO350’s progress in treating mild-to-moderate psoriasis and continued global sales of ROMEGA nutraceutical ingredients and finished goods. Investors should therefore treat this as an incremental financing housekeeping item and focus attention on upcoming clinical milestones, remaining convertible facility utilization, and any additional capital-raising announcements that would produce larger dilution or improve liquidity materially.

Key Decisions for Investors

• Monitor the cadence and scale of further conversions from the NOK 15.0 million facility and require disclosure of remaining facility drawdown before materially increasing exposure
• Given the conversion’s negligible balance-sheet impact, maintain or modestly size positions if your thesis is pipeline-driven—consider buying only ahead of near-term HRO350 clinical or commercial catalysts
• Request clarity from management on cash runway and planned capital-raising plans and consider hedging or setting risk limits if additional equity issuance appears likely